February 15th 2012
£445 / $690 / €530
The affordable desk reference for easily reviewing the state of the global CNS drug development landscape
The CNS pipeline is second only to cancer in terms of the number of pharmaceuticals in development. Espicom has looked at Phases I, II and III of the clinical development programme and has identified more than 270 agents. These include new chemical entities and biologicals, as well as novel formulations of known drugs and new indications for approved drugs in lifecycle development. While many more are in preclinical development, this report focuses on pharmaceuticals that have progressed to clinical studies in humans.
With this report you can instantly...
While you can choose print or pdf, you will get – at no extra charge – access in Espicom Interactive, an advanced search and display interface. Make your investment in this report really pay, with valuable and practical user benefits, including: